Hu Kun, Zhang Yu, Chen Wan, Chen Hui, Wang Qiwei, He Anqi, Qin Tingfeng, Li Xin, Xia Ling, Liu Yizhi, Chen Weirong
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Department of Ophthalmology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing, China.
JAMA Ophthalmol. 2025 May 15. doi: 10.1001/jamaophthalmol.2025.1080.
The optimal timing for secondary intraocular lens (IOL) implantation in children with bilateral aphakia remains uncertain, with important implications for long-term visual outcomes and the risk of complications such as glaucoma. Determining when to implant to achieve the best visual outcomes while minimizing complications is critical for improving clinical decision-making in pediatric cataract management.
To report the visual acuity (VA) and complications in children with bilateral aphakia after lensectomy for pediatric cataracts, undergoing secondary IOL implantation at different ages.
DESIGN, SETTING, AND PARTICIPANTS: This single-center prospective observational cohort study, conducted from 2014 to 2023, is a 7-year follow-up study. A total of 251 children met the inclusion criteria. After exclusion, 158 children were enrolled in this study. These 158 children (316 eyes) underwent lensectomy before the age of 2 years, followed by secondary IOL implantation between the ages of 2 and younger than 6 years in bilateral pediatric cataracts.
Study participants were categorized into 4 groups based on the timing of secondary IOL implantation (2 to <3 years, 3 to <4 years, 4 to <5 years, and 5 to <6 years).
Best-corrected VA (BCVA) outcomes at age 7 years after secondary IOL implantation in children with bilateral pediatric cataracts.
Among the 158 children included in the study, 103 (65.2%) were male. At age 7 years, the mean (SD) BCVA for children who underwent secondary IOL implantation was 0.49 (0.35) logMAR (Snellen equivalent, 20/62) at 2 to younger than 3 years, 0.59 (0.36) logMAR (Snellen equivalent, 20/78) at 3 to younger than 4 years, 0.60 (0.30) logMAR (Snellen equivalent, 20/80) at 4 to younger than 5 years, and 0.65 (0.34) logMAR (Snellen equivalent, 20/89) at 5 to younger than 6 years (P = .20). Glaucoma-related adverse events occurred in 47 eyes in total: 6 eyes (8.8%), 7 eyes (9.0%), 10 eyes (15.6%), and 24 eyes (22.6%) across the groups, respectively, with a statistical difference among the groups (P = .03).
These findings suggest that secondary IOL implantation performed between the ages of 2 and younger than 6 years following bilateral pediatric cataract lensectomy can achieve comparable visual outcomes; however, the risk of glaucoma increases with older implantation age.
双侧无晶状体儿童二期人工晶状体(IOL)植入的最佳时机仍不确定,这对长期视觉效果以及青光眼等并发症的风险具有重要影响。确定何时植入以实现最佳视觉效果并将并发症降至最低,对于改善小儿白内障治疗的临床决策至关重要。
报告小儿白内障晶状体切除术后双侧无晶状体儿童在不同年龄接受二期IOL植入后的视力(VA)和并发症情况。
设计、地点和参与者:这项单中心前瞻性观察队列研究于2014年至2023年进行,为期7年的随访研究。共有251名儿童符合纳入标准。排除后,158名儿童纳入本研究。这158名儿童(316只眼)在2岁前接受了晶状体切除术,随后在双侧小儿白内障中于2至6岁以下接受二期IOL植入。
根据二期IOL植入时间,研究参与者分为4组(2至<3岁、3至<4岁、4至<5岁和5至<6岁)。
双侧小儿白内障儿童二期IOL植入后7岁时的最佳矫正视力(BCVA)结果。
在纳入研究的158名儿童中,103名(65.2%)为男性。在7岁时,接受二期IOL植入的儿童中,2至<3岁组的平均(标准差)BCVA为0.49(0.35)logMAR(Snellen等效值,20/62),3至<4岁组为0.59(0.36)logMAR(Snellen等效值,20/78),4至<5岁组为0.60(0.30)logMAR(Snellen等效值,20/80),5至<6岁组为0.65(0.34)logMAR(Snellen等效值,20/89)(P = 0.20)。青光眼相关不良事件共发生在47只眼中:各组分别为6只眼(8.8%)、7只眼(9.0%)、10只眼(15.6%)和24只眼(22.6%),组间存在统计学差异(P = 0.03)。
这些发现表明,双侧小儿白内障晶状体切除术后在2至6岁以下进行二期IOL植入可获得相当的视觉效果;然而,青光眼风险随植入年龄增大而增加。